Bristol Myers Squibb plans to launch COBENFY^TM (xanomeline and trospium chloride) in the UK at the US price, a first for the company

September 22, 2025

Today, Bristol Myers Squibb announced plans to launch COBENFY^TM (xanomeline and trospium chloride), in the UK in 2026 at the US list price, to reflect the value of this medicine for patients and society. This approach underscores President Trump’s call for other countries to pay their fair share for American innovation.

“We agree with the Trump Administration that other countries need to pay their fair share,” said Adam Lenkowsky, Chief Commercialization Officer, Bristol Myers Squibb. “By making this commitment, we are asking the UK to step up in recognizing the value of truly innovative therapies.”

Bristol Myers Squibb plans to submit a marketing authorization application to the Medicines and Healthcare products Regulatory Agency (MHRA) later this year, via the International Recognition Procedure (IRP). This fast-track route enables accelerated approval by leveraging its prior Food and Drug Administration (FDA) approval.

Lenkowsky noted, “Our intention is to work with the UK health authorities to make this medicine available, but we are prepared to make the difficult decision to walk away if they cannot better recognize the value our medicine brings to patients and society.”